HANALL BIOPHARMA CO.,LTD

009420KOSPIPharmaceuticals

HANALL BIOPHARMA CO.,LTD (009420, KOSPI) reported KRW 155bn revenue in 2025.

Broker research: target prices and ratings

2 reports from 2 firms between 2026-09-28 and 2026-09-28. One firm stated a target price: KRW 70,000.

Newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.

DateTarget priceRatingFirmAnalyst
Not statedNot statedKiwoom SecuritiesNot stated
KRW 70,000BuyIBK Investment & SecuritiesJung I-su

Analyst names are our Roman spellings of the Korean names on the listing; the analyst may spell their name differently. Where the listing gave no name, we took it from Hankyung Consensus only when the date, firm and ticker pointed to exactly one report.

Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.

This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.

Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.

Compare target prices across Korean biotech and pharma stocks →

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2021102109198163Consolidated
202211020213168Consolidated
202313524240186Consolidated
20241390-2213168Consolidated
2025155-1-6225162Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
20219.9%8.8%82.4%5.4%
20221.4%0.2%78.8%0.1%
20231.6%2.6%77.7%1.9%
20240.2%-1.3%79.1%-1.1%
2025-0.6%-3.6%71.8%-3.4%

Revenue moved 52.7% between 2021 and 2025.

Net profit was negative in the 2 most recent consecutive years on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 2,837bn
Close priceKRW 54,300
Listed shares52,240,638
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Jung Seung-won (정승원)Co-Representative Director (CEO)Inside director5 years
Park Su-jin (박수진)Co-Representative Director (CEO)Inside director2 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)315
Women104 (33%)
Average tenure15.1 years
Annual pay, menKRW 87,530,806
Annual pay, womenKRW 70,846,154
Pay ratio, women to men80.9%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →